It’s Time to Build
in Bio
Our ability to engineer biology is fundamentally transforming how we diagnose, treat, and manage disease. Advances in drug development, from AI-driven discovery to entirely new therapeutic modalities, are unlocking treatments for both rare diseases and some of the most widespread, complex conditions—cardiovascular, autoimmune, and chronic diseases.
Biology remains one of the greatest frontiers of innovation. As technology unlocks new ways to fight disease, the impact will extend far beyond the lab—transforming how we detect illness earlier, develop more effective treatments, and ultimately change the trajectory of human health.
a16z is a tech/bio pioneer uniquely providing a unified perspective to their companies.
Daphne Koller Founder & CEO, Insitro
a16z has been a key partner building a next-gen biotech company.
Ramsey Homsany Cofounder & President, Octant Bio
a16z brings strategic thought and tactical backup that is often needed.
Benjamin Oakes, PhD Cofounder, President & CEO, Scribe Therapeutics
The team is a great source of connections and strategic insights.
Kevin Parker Cofounder & CEO, Cartography
a16z is an innovative firm that teaches and supports founders.
Eric Kelsic Founder & CEO, Dyno Therapeutics
Bio Builders
Portfolio Jobs BoardAny investments or portfolio companies mentioned, referred to, or described on this page are not representative of all investments in vehicles managed by a16z and there can be no assurance that the investments will be profitable or that other investments made in the future will have similar characteristics or results. Exits include current and former a16z portfolio companies which have been acquired as well as companies which have undergone an initial public offering or direct public offering of shares. Certain publicly traded companies on this list may still be held in Andreessen Horowitz funds. A list of investments made by funds managed by a16z is available here: https://a16z.com/investment-list/. Additionally investments that have participated in a16z accelerator programs can also be found here: https://speedrun.a16z.com/companies/. Excluded from this list are investments for which the issuer has not provided permission for a16z to disclose publicly as well as unannounced investments in publicly traded digital assets. Further, the list of investments is updated monthly and as such may not reflect most recent a16z investments. Past results of Andreessen Horowitz’s investments, pooled investment vehicles, or investment strategies are not necessarily indicative of future results.
Themes in Bio+Health
Investing in Stipple Bio
Andrew Huberman: Peptides, Sleep Tech, and the End of Obesity
Deploying AI in Healthcare
Investing in Ease
Infinite Healthcare: What’s It Worth?
Novartis CEO Vasant Narasimhan on Transforming a 250-Year-Old Company
Why America’s Health Crisis Is an Incentive Problem
Investing in Phylo
Healthcare 2026: AI Doctors, GLP-1s, and Insurance Defection
Investing in Protege AI
Wartime vs Peacetime: Ben Horowitz on Leadership
Big Ideas 2026: New Infrastructure Primitives
Big Ideas 2026: Voice Agents and High-Stakes Trust
Investing in Truemed
Investing in Leona
Investing in Aradigm
Function Health Series B: Launching the Medical Intelligence Era
Biology Is Eating the World
Sign up for our bio + health newsletter to get the latest take from us on the future of biology, technology, and care delivery.
Biology Is Eating the World
Sign up for our bio + health newsletter to get the latest take from us on the future of biology, technology, and care delivery.